Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907415" target="_blank" >RIV/00216208:11120/13:43907415 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1111/ijcp.12147" target="_blank" >http://dx.doi.org/10.1111/ijcp.12147</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ijcp.12147" target="_blank" >10.1111/ijcp.12147</a>

Result language
angličtina
Original language name
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
Original language description
Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drugdrug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)